U.S. markets closed

Capitala Finance Corp. (CPTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.55+0.35 (+2.46%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close14.20
Open14.10
Bid14.00 x 1400
Ask14.88 x 800
Day's Range13.44 - 14.86
52 Week Range8.40 - 55.20
Volume44,904
Avg. Volume28,157
Market Cap39.446M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-13.33
Earnings DateMar 01, 2021 - Mar 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 20, 2020
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Where Do Hedge Funds Stand On Capitala Finance Corp (CPTA)?
    Insider Monkey

    Where Do Hedge Funds Stand On Capitala Finance Corp (CPTA)?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

  • Capitala Group’s Partnership with Veteran Leadership is a Prescription for Success
    GlobeNewswire

    Capitala Group’s Partnership with Veteran Leadership is a Prescription for Success

    CHARLOTTE, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Capitala Group (“Capitala”), a leading provider of capital to lower middle market companies, announced today that it has successfully exited its senior secured debt and minority equity investment in Option Rx, an owner and operator of specialty compounding pharmacies across the United States. Originally provided in partnership with Cold Bore Capital, the investment funded the company’s next phase of growth as it acquired specialty pharmacies across the country. Based out of Nashville, TN, Optio Rx currently specializes in providing medication and care in the fertility, veterinary, dermatology, hormone replacement and hospice industries.“Everyone at Capitala is especially proud to announce this successful exit today, as we celebrate Veterans Day 2020, and our partnership with Cold Bore Capital in this deal,” stated Adam Richeson, Managing Director at Capitala. “Cold Bore Capital is a veteran-led private equity firm that partners exceptional business owners with elite military leaders to preserve the legacies of family-owned businesses like Optio Rx.”About Capitala GroupCapitala Group is a $3.0 billion asset management firm that has been providing capital to lower middle market companies throughout North America for over twenty years. Since our inception in 1998, Capitala has invested in over 165 companies and seeks to partner with strong management teams to create value and generate superior risk-adjusted returns for our individual and institutional investors. For more information, definitions and details visit our website at www.CapitalaGroup.com.Contacts: Steve Arnall CFO | Investor Relations sarnall@capitalagroup.comKatina Cole Jakubowski Marketing | Communications kjakubowski@capitalagroup.com

  • Capitala Finance (CPTA) Surpasses Q3 Earnings and Revenue Estimates
    Zacks

    Capitala Finance (CPTA) Surpasses Q3 Earnings and Revenue Estimates

    Capitala Finance (CPTA) delivered earnings and revenue surprises of 86.67% and 3.57%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?